We are live on ! Find out more
LPCN icon

Lipocine
LPCN

47 hedge funds and large institutions have $24.9M invested in Lipocine in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 2

90% more capital invested

Capital invested by funds: $13.1M → $24.9M (+$11.8M)

81% more funds holding

Funds holding: 26 → 47 (+21)

13.36% more ownership

Funds ownership: 29.36% → 42.72% (+13%)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

Holders
47
Holders Change
+21
Holders Change %
+80.77%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
9
Reduced
10
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
IC
Ikarian Capital
Texas
+$2.69M
2
EP
Eversept Partners
New York
+$2.57M
3
RA
Rosalind Advisors
Ontario, Canada
+$1.93M
4
ACM
AIGH Capital Management
Maryland
+$1.74M
5
SC
Stempoint Capital
New York
+$1.4M

Top Sellers

1
DP
Diadema Partners
New Jersey
-$1.84M
2
SCM
Squadron Capital Management
Illinois
-$697K
3
PAP
Persistent Asset Partners
Hong Kong
-$498K
4
Ameriprise
Ameriprise
Minnesota
-$40.6K
5
UBS Group
UBS Group
Switzerland
-$18.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
1
Ikarian Capital
Texas
$4.06M +$2.69M +309,014 +155%
SCM
2
Squadron Capital Management
Illinois
$3.6M -$697K -80,000 -15%
EP
3
Eversept Partners
New York
$2.36M +$2.57M +294,989 New
RA
4
Rosalind Advisors
Ontario, Canada
$1.77M +$1.93M +221,616 New
VCM
5
Vanguard Capital Management
Pennsylvania
$1.6M +$1.75M +200,668 New
ACM
6
AIGH Capital Management
Maryland
$1.6M +$1.74M +200,000 New
SC
7
Stempoint Capital
New York
$1.28M +$1.4M +160,420 New
BFM
8
Boothbay Fund Management
New York
$1.12M +$746K +85,594 +156%
SFCM
9
Seven Fleet Capital Management
California
$998K +$1.09M +124,942 New
BC
10
Birchview Capital
Vermont
$893K +$974K +111,786 New
BlackRock
11
BlackRock
New York
$713K – – –
MBAM
12
Mink Brook Asset Management
Florida
$534K +$582K +66,812 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$505K +$5.97K +685 +1%
EAM
14
Exome Asset Management
New York
$486K +$530K +60,861 New
DP
15
Diadema Partners
New Jersey
$400K -$1.84M -210,939 -81%
JGC
16
J. Goldman & Co
New York
$337K +$367K +42,170 New
Renaissance Technologies
17
Renaissance Technologies
New York
$308K +$9.58K +1,100 +3%
Two Sigma Investments
18
Two Sigma Investments
New York
$270K +$294K +33,750 New
VFT
19
Vanguard Fiduciary Trust
Pennsylvania
$259K +$282K +32,413 New
Citadel Advisors
20
Citadel Advisors
Florida
$232K +$253K +29,088 New
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$199K -$9 -1 -0%
ACM
22
ADAR1 Capital Management
Texas
$185K +$202K +23,180 New
State Street
23
State Street
Massachusetts
$179K +$32.9K +3,781 +20%
Jane Street
24
Jane Street
New York
$160K +$82.4K +9,453 +89%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$153K +$60.8K +6,982 +58%
1
2

LPCN Hedge Fund Activity: Q1 2026 in Review

47 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2026, worth a combined $24.9M — up 90% from $13.1M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new LPCN positions and 2 closed out — a net gain of 22 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $2.69M. The largest seller was Diadema Partners, cutting an estimated $1.84M.

  • 47 institutional investors held Lipocine (LPCN) as of Q1 2026, up from 26 in Q4 2025.
  • Funds reported $24.9M of Lipocine stock for Q1 2026, up 90% quarter-over-quarter.
  • 24 funds opened new Lipocine positions in Q1 2026 and 2 closed out, a net change of +22 holders.
  • The largest Lipocine buyer in Q1 2026 was Ikarian Capital, an estimated $2.69M added.
  • The largest Lipocine seller in Q1 2026 was Diadema Partners, an estimated $1.84M sold.

Based on aggregated 13F filings for Q1 2026.